Compare YDDL & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDDL | CCCC |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | Philippines | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.4M | 240.3M |
| IPO Year | 2025 | 2020 |
| Metric | YDDL | CCCC |
|---|---|---|
| Price | $5.40 | $2.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 65.3K | ★ 1.7M |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 310.92 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $62,922,700.00 | $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.00 | ★ N/A |
| Revenue Growth | ★ 118.15 | N/A |
| 52 Week Low | $3.61 | $1.09 |
| 52 Week High | $8.89 | $4.26 |
| Indicator | YDDL | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.48 |
| Support Level | N/A | $1.87 |
| Resistance Level | N/A | $2.19 |
| Average True Range (ATR) | 0.00 | 0.13 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 79.35 |
One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of Philippines. The company process raw materials and generate final products that include copper alloy ingot, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap and industrial recycling. By providing lower-cost alternatives for processing recycled materials, It is not only Contributing to environmental sustainability but also highlight its role as a modern and specialized recycling company.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.